Cellular immune responses to helper-free HSV-1 amplicon particles encoding HIV-1 gp120 are enhanced by DNA priming

Vaccine

Volumn 21, Issue 19-20, 2003, Pages 2288-2297

  Wang, Xiuqing ^a,c   Wiley, Rebecca D ^a,d   Evans, Thomas G ^b,e   Bowers, William J ^a   Federoff, Howard J ^a   Dewhurst, Stephen ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SOUTH DAKOTA STATE UNIVERSITY   (United States)

^d BOSTON UNIVERSITY   (United States)

^e VICAL INC   (United States)

Author keywords

HIV vaccine; HSV 1 amplicon vector; Prime boost

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PRIMER DNA; VIRUS VECTOR;

AMPLICON; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL KINETICS; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; GENETIC CODE; HERPES SIMPLEX VIRUS 1; IMMUNIZATION; INOCULATION; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAINING; T LYMPHOCYTE ACTIVATION;

EID: 0037727613     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00099-9     Document Type: Article

References (29)

1. Borrow P., Lewicki H., Hahn B.H., Shaw G.M., Oldstone M.B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68(9):1994;6103-6110.
2. Ogg G.S., Jin X., Bonhoeffer S.et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 279(5359):1998;2103-2106.
3. Jin X., Bauer D.E., Tuttleton S.E.et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189(6):1999;991-998.
4. Schmitz J.E., Kuroda M.J., Santra S.et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 283(5403):1999;857-860.
5. Seth A., Ourmanov I., Schmitz J.E.et al. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J. Virol. 74(6):2000;2502-2509.
6. Amara R.R., Villinger F., Altman J.D.et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 292(5514):2001;69-74.
7. Barouch D.H., Santra S., Schmitz J.E.et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science. 290(5491):2000;486-492.
8. Shiver J.W., Fu T.M., Chen L.et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 415(6869):2002;331-335.
9. Rose N.F., Marx P.A., Luckay A.et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell. 106(5):2001;539-549.
10. Haglund K., Leiner I., Kerksiek K., Buonocore L., Pamer E., Rose J.K. Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 gag and env proteins. J. Virol. 76(15):2002;7506-7517.
11. Haglund K., Leiner I., Kerksiek K., Buonocore L., Pamer E., Rose J.K. High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses. J. Virol. 76(6):2002;2730-2738.
12. Hanke T., Blanchard T.J., Schneider J.et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine. 16(5):1998;439-445.
13. Hanke T., Samuel R.V., Blanchard T.J.et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J. Virol. 73(9):1999;7524-7532.
14. Caver T.E., Lockey T.D., Srinivas R.V., Webster R.G., Hurwitz J.L. A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation. Vaccine. 17(11/12):1999;1567-1572.
15. Wee E.G., Patel S., McMichael A.J., Hanke T. A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques. J. Gen. Virol. 83(Pt 1):2002;75-80.
16. Hocknell P.K., Wiley R.D., Wang X.et al. Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses. J. Virol. 76(11):2002;5565-5580.
17. Geller A.I., Breakefield X.O. A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons. Science. 241(4873):1988;1667-1669.
18. Matzinger P. The JAM test. A simple assay for DNA fragmentation and cell death. J. Immunol. Methods. 145(1/2):1991;185-192.
19. Shi Y., Rock K.L. Cell death releases endogenous adjuvants that selectively enhance immune surveillance of particulate antigens. Eur. J. Immunol. 32(1):2002;155-162.
20. Shi Y., Zheng W., Rock K.L. Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc. Natl. Acad. Sci. U.S.A. 97(26):2000;14590-14595.
21. Letvin N.L. Strategies for an HIV vaccine. J. Clin. Invest. 110(1):2002;15-27.
22. McMichael A., Hanke T. The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible? Nat. Rev. Immunol. 2(4):2002;283-291.
23. De Boer R.J., Oprea M., Antia R., Murali-Krishna K., Ahmed R., Perelson A.S. Recruitment times, proliferation, and apoptosis rates during the CD8(+) T-cell response to lymphocytic choriomeningitis virus. J. Virol. 75(22):2001;10663-10669.
24. Murali-Krishna K., Altman J.D., Suresh M.et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity. 8(2):1998;177-187.
25. Brand D., Lemiale F., Turbica I., Buzelay L., Brunet S., Barin F. Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles. AIDS Res. Hum. Retroviruses. 14(15):1998;1369-1377.
26. Finkelman F.D., Holmes J., Katona I.M.et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu. Rev. Immunol. 8:1990;303-333.
27. Stevens T.L., Bossie A., Sanders V.M.et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature. 334(6179):1988;255-258.
28. McKendall R.R., Woo W. Murine IgG subclass responses to herpes simplex virus type 1 and polypeptides. J. Gen. Virol. 69(Pt 4):1988;847-857.
29. McKendall R.R., Woo W. Antibody activity to herpes simplex virus in mouse Ig classes and IgG subclasses. Arch. Virol. 98(3/4):1988;225-233.